mk 677 vs sermorelin: Frequently asked questions

Sermorelin is the better choice. MK-677 is a ghrelin receptor agonist, and ghrelin is the primary endogenous orexigenic (appetite-stimulating) hormone. Virtually all subjects on MK-677 report increased hunger, particularly within 60–90 minutes of dosing. This effect is dose-dependent and unavoidable given the mechanism. Sermorelin, as a GHRH analogue, does not activate ghrelin pathways and produces minimal appetite impact. Research focusing on lean tissue accretion or metabolic function without caloric surplus would favour Sermorelin.

Sermorelin is mandatory. MK-677 produces non-pulsatile, sustained GH elevation. This is pharmacologically useful in some contexts but does not replicate the physiological pattern of endogenous GH secretion, which occurs in discrete pulses primarily during slow-wave sleep. Research investigating circadian GH dynamics, sleep-related GH secretion, or interventions meant to restore age-related loss of GH pulsatility must use Sermorelin or another GHRH analogue. MK-677's steady-state elevation obscures the very variable the study is designed to measure.

MK-677 is the only option. No GHRH analogue, including Sermorelin, has oral bioavailability. The peptide structure is degraded by gastric proteases before reaching systemic circulation. MK-677 is a non-peptide small molecule designed specifically for oral absorption, with approximately 60–70% bioavailability when taken on an empty stomach. Protocols involving elderly subjects, paediatric populations, or any scenario where daily injections are impractical favour MK-677 for compliance reasons.

Select MK-677. Sermorelin requires functional GHRH receptors on anterior pituitary somatotrophs to trigger GH release. If the pituitary is atrophied, damaged, or receptor-downregulated, Sermorelin will produce a blunted or absent GH response. MK-677 bypasses the hypothalamic-pituitary axis entirely by acting on ghrelin receptors, making it effective even in subjects with pituitary dysfunction. Diagnostic testing using Sermorelin can confirm pituitary insufficiency, but therapeutic protocols in such cases would require either MK-677 or exogenous GH.

If your protocol already involves daily subcutaneous administration (co-administration with other peptides, for example), Sermorelin's injection requirement isn't a disadvantage. In that case, choose based on mechanism: do you need continuous elevation (MK-677) or amplified natural pulses (Sermorelin)? Administration route becomes irrelevant when both fit the existing protocol.

Use Sermorelin. Peak GH elevation occurs 15–30 minutes post-injection and can reach 3–10× baseline depending on dose and individual pituitary responsiveness. This acute response allows precise temporal measurement of GH secretion capacity. MK-677 produces sustained elevation rather than discrete peaks. It's the wrong tool if you're trying to quantify maximal secretory burst amplitude or test pituitary reserve.

MK-677 maintains efficacy with chronic dosing. Clinical trials have shown sustained IGF-1 elevation for 12–18 months without tachyphylaxis. Sermorelin, by contrast, may exhibit receptor desensitization with continuous daily use beyond 8–12 weeks, requiring dose escalation or periodic washout periods to restore response. For extended metabolic or body composition studies, MK-677's pharmacological stability reduces the need for protocol adjustments mid-trial.

MK-677 eliminates cold-chain logistics entirely. Lyophilized powder is stable at room temperature indefinitely, and once reconstituted (if using injectable form), it remains stable for weeks without refrigeration. Sermorelin loses potency rapidly at ambient temperature. A 24-hour temperature excursion above 8°C can reduce bioactivity by 15–25%. Field research, multi-site trials, or studies in resource-limited settings favor MK-677 for this reason.